MedTrace Logo

Transcatheter Aortic Valve Replacement for Pure Severe Aortic Valve Regurgitation

NCT06381271 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2024-04-24

No results posted yet for this study

Summary

The purpose of this multicenter, prospective and observational registry is to evaluate the safety and efficacy of TAVR for treatment of pure severe aortic valve regurgitation. Baseline characteristics, procedural and clinical data will be collected

Conditions

  • Aortic Valve Regurgitation

Interventions

PROCEDURE

Transcatheter aortic valve replacement

A total of 500 consecutive patients with NAVR undergoing TAVR will be enrolled at 3-5 centers. Clinical follow-up will be conducted in the periprocedural and after aortic valve implantation at 1 month, 1 year, 2 years, 3 years, 4 years, 5 years, and 10 years

Sponsors & Collaborators

  • Xijing Hospital

    lead OTHER

Principal Investigators

  • Ling Tao, M.D, Ph.D · Xijing Hospital

  • Rutao Wang, M.D, Ph.D · Xijing Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-30
Primary Completion
2034-10-31
Completion
2034-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06381271 on ClinicalTrials.gov